Chong Kun Dang Pharmaceutical Corp.
185750 | KO
Overview
Corporate Details
- ISIN(s):
- KR7185750007
- LEI:
- Country:
- South Korea
- Address:
- 서울 서대문구 충정로3가 3가 368 종근당빌딩, 서대문구
- Website:
- https://www.ckdpharm.com
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
No description available.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-08-29 00:00 |
Regulatory Filings
투자판단관련주요경영사항 (텔미누보정(CKD828) 식품의약품안전처 국내 품목허가 승인)
|
Korean | 7.2 KB | ||
| 2025-08-22 00:00 |
Regulatory Filings
투자판단관련주요경영사항 (텔미누보정(CKD828) 식품의약품안전처 국내 품목허가 신청)
|
Korean | 13.5 KB | ||
| 2025-08-14 00:00 |
Interim / Quarterly Report
반기보고서 (2025.06)
|
Korean | 4.9 MB | ||
| 2025-08-01 00:00 |
Earnings Release
영업(잠정)실적(공정공시)
|
Korean | 13.3 KB | ||
| 2025-07-24 00:00 |
Governance Information
공정거래자율준수프로그램운영현황(안내공시)
|
Korean | 15.8 KB | ||
| 2025-06-24 00:00 |
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
|
Korean | 99.9 KB | ||
| 2025-06-12 00:00 |
Regulatory Filings
유형자산취득결정
|
Korean | 7.9 KB | ||
| 2025-06-12 00:00 |
Regulatory Filings
풍문또는보도에대한해명(미확정)
|
Korean | 8.0 KB | ||
| 2025-06-10 00:00 |
Regulatory Filings
풍문또는보도에대한해명(미확정)
|
Korean | 6.2 KB | ||
| 2025-06-02 00:00 |
Governance Information
기업지배구조보고서공시
|
Korean | 1.8 MB | ||
| 2025-05-22 00:00 |
Regulatory Filings
기타경영사항(자율공시) (CKD510 기술수출 관련 마일스톤 수령)
|
Korean | 5.2 KB | ||
| 2025-05-15 00:00 |
Quarterly Report
분기보고서 (2025.03)
|
Korean | 2.9 MB | ||
| 2025-04-30 00:00 |
Earnings Release
영업(잠정)실적(공정공시)
|
Korean | 13.3 KB | ||
| 2025-04-23 00:00 |
Regulatory Filings
투자판단관련주요경영사항 (듀비엠폴서방정(CKD383) 식품의약품안전처 국내 품목허가 신청)
|
Korean | 16.9 KB | ||
| 2025-04-23 00:00 |
Regulatory Filings
투자판단관련주요경영사항 (듀비엠파정(CKD398) 식품의약품안전처 국내 품목허가 신청)
|
Korean | 16.6 KB |
Automate Your Workflow. Get a real-time feed of all Chong Kun Dang Pharmaceutical Corp. filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for Chong Kun Dang Pharmaceutical Corp.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Chong Kun Dang Pharmaceutical Corp. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
Developing long-acting therapies for rare allergic and immunologic diseases like HAE.
United States of America
ATXS
United States of America
ATXS
Clinical-stage biopharma creating novel psychedelic drugs for mental health disorders.
United States of America
ATAI
United States of America
ATAI
A clinical-stage biopharma developing oral antiviral therapies for viruses like Hepatitis C.
United States of America
AVIR
United States of America
AVIR
Developing small-molecule therapies to slow neurodegeneration in diseases like Alzheimer's.
United States of America
ATHA
United States of America
ATHA
Clinical-stage biopharma developing (Z)-endoxifen for breast cancer treatment and prevention.
United States of America
ATOS
United States of America
ATOS
Developing novel medicines for fibrosis and inflammation using tRNA synthetase biology.
United States of America
ATYR
United States of America
ATYR
Developing virus-like therapies to selectively destroy solid tumors in ocular & urologic oncology.
United States of America
AURA
United States of America
AURA
Biopharma developing therapies for autoimmune and kidney diseases like lupus nephritis.
United States of America
AUPH
United States of America
AUPH
A global producer and seller of medical and recreational cannabis and derivative products.
United States of America
ACB
United States of America
ACB
Develops programmed CAR T-cell therapies for cancer and autoimmune diseases.
United States of America
AUTL
United States of America
AUTL